2020 and the year ahead for PE investments in health care and life sciences

Viewpoints
February 2, 2021
1 minutes
Authors:

The COVID-19 pandemic has transformed the business landscape across the health care and life sciences industries, and is continuing to do so. The profound shifts that have resulted from the nearly overnight change in the needs, priorities and capabilities of patients, consumers and industry players worldwide will be felt long after the pandemic wanes. In the health care and life sciences industries, the transformative effects of COVID-19 have, in some cases, accelerated change already underway and, in other cases, reoriented it.

Ropes & Gray’s market-leading global health care and life sciences industry teams assisted clients throughout 2020 as they reacted and readjusted to, and invested into, the changed landscape. In recognition of the firm’s work, Financial Times named Ropes & Gray the leading law firm for guiding clients through the COVID-19 pandemic.

A few of the business and legal trends that we have seen within the health care and life sciences industries during 2020 are set out here. We expect Private Equity / M&A activity to continue to be robust throughout 2021 as a result of these trends and other changing dynamics.